CD8A and head and neck squamous cell carcinoma: Our findings not only enrich our understanding of the immune uniqueness of MAPK-mutated HNSCC tumors in patients but also highlights the potential clinical utility of MAPK pathway mutations in identifying HNSCC patients with CD8+ T-cell–inflamed tumors, independent of TMB, for likely beneficial PD1/PD-L1 inhibitor treatments.